Base Metals Investing Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Base Metals Investing OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Base Metals Investing Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Base Metals Investing Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
